LMR Partners’s Catalyst Pharmaceutical CPRX Stock Holding History

LMR Partners’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-112,476	Closed	-$79K	–	362
2016 Q2	$79K	Buy	+112,476	New	+$90.6K	0.01%	414

Other funds holding CPRX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

TCM

Tanaka Capital Management New York $59.9M AUM

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

LMR Partners's CPRX Position: Q3 2016 in Review

LMR Partners sold out of Catalyst Pharmaceutical (CPRX) in Q3 2016, closing a stake of 112,476 shares — an estimated $79K sold.

LMR Partners first reported a position in CPRX in Q2 2016 and held it in 1 quarter. The position peaked at $79K in Q2 2016. 49 funds tracked by Wall St. Rank hold CPRX as of Q3 2016.

LMR Partners reported no remaining Catalyst Pharmaceutical position as of Q3 2016 after selling out during the quarter.
LMR Partners sold 112,476 Catalyst Pharmaceutical shares in Q3 2016, an estimated $79K.
LMR Partners first reported a position in Catalyst Pharmaceutical in Q2 2016 and held it in 1 quarter.
LMR Partners's Catalyst Pharmaceutical position peaked at $79K in Q2 2016.
49 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2016.

Based on LMR Partners's 13F filing for Q3 2016, filed 1 Nov 2016.